🏛️ Verified NIH Record • Updated 2026-04-23
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) (NCT04982393)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Alnylam Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Phoenix, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Clinical Trial Site — Phoenix, Arizona
- Clinical Trial Site — Washington D.C., District of Columbia
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Rochester, Minnesota
- Clinical Trial Site — Cincinnati, Ohio
- Clinical Trial Site — Pittsburgh, Pennsylvania
- Clinical Trial Site — Dallas, Texas
- Clinical Trial Site — Houston, Texas
- Clinical Trial Site — Ghent,
- Clinical Trial Site — Liège,
- Clinical Trial Site — Hamilton, Ontario
- Clinical Trial Site — Toronto, Ontario
- Clinical Trial Site — Laurier, Quebec
- Clinical Trial Site — Bordeaux,
- Clinical Trial Site — Lyon,
- Clinical Trial Site — Paris,
- Clinical Trial Site — Berlin,
- Clinical Trial Site — Cologne,
- Clinical Trial Site — Hamburg,
- Clinical Trial Site — Jerusalem,
- Clinical Trial Site — Orbassano, Torino
- Clinical Trial Site — Milan,
- Clinical Trial Site — Verona,
- Clinical Trial Site — Amsterdam,
- Clinical Trial Site — Santa Cruz de Tenerife, Canary Islands
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Hyperoxaluria Type 1
- Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD — San Francisco, California
- Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) — Birmingham, Alabama
Explore by condition: All Primary Hyperoxaluria Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.